Turning Point Therapeutics Stock Price

-3.53 (-4.53%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Turning Point Therapeutics Inc TPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-3.53 -4.53% 74.47 20:00:00
Open Price Low Price High Price Close Price Prev Close
77.61 74.35 77.61 74.47 78.00
Bid Price Ask Price Spread News
74.00 90.55 16.55 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,777 212,768 $ 75.61 $ 16,087,773 - 59.73 - 141.30
Last Trade Time Type Quantity Stock Price Currency
16:00:06 2 $ 74.47 USD


Draw Mode:

Turning Point Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.68B 49.41M 41.02M $ 25.00M $ - -3.96 -22.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 84.14k 4.70%

more financials information »

Turning Point Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week79.1381.7874.3578.08317,849-4.66-5.89%
1 Month76.1582.2074.3578.32266,859-1.68-2.21%
3 Months77.8282.2059.7370.83309,304-3.35-4.3%
6 Months99.3599.3559.7374.24432,475-24.88-25.04%
1 Year83.26141.3059.7391.01393,773-8.79-10.56%
3 Years27.98141.3025.9970.58361,32846.49166.15%
5 Years27.98141.3025.9970.58361,32846.49166.15%

Turning Point Therapeutics Description

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Your Recent History
Turning Po..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.